Overview

Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)

Status:
Completed

Trial end date:
2016-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability of multiple doses of ND-L02-s0201 in subjects with moderate to extensive hepatic fibrosis.

Phase:

Phase 1

Details

Lead Sponsor:

Bristol-Myers Squibb
Nitto Denko Corporation

Collaborator:

Nitto Denko Corporation